АРИЛКОНДЕНСИРОВАННЫЕ АЗАПОЛИЦИКЛИЧЕСКИЕ СОЕДИНЕНИЯ

... 1. Соединения формулы (I) где R1 представляет собой -COOR4, где R4 представляет собой группу формулы R2 и R3, вместе с бензольным кольцом, к которому они присоединены, образуют бициклическую кольцевую систему, выбранную из следующих: где один из атомов углерода кольца А необязательно может быть замещен кислородом или N(C1-C6)алкилом; где R11 и R12 выбирают, независимо, из водорода, (C1-C6)алкила; и (C1-C6)алкокси(C0-C6)алкила-, в котором общее число атомов углерода не превышает шесть, и где любая из алкильных групп необязательно может быть замещена одним-семью атомами фтора; нитро, циано, галогена, амино, (C1-C6 )алкиламино-, ((C1-C6 )алкил)2амино-, -СО2R5, -CONR6R7, -SO2NR8R9, -C(=O)R10, -XC(=O)R10, фенила, моноциклического гетероарила, или, когда они связаны с атомом азота, группы формулы каждый R5, R6, R7, R8, R9 и R10 выбирают, независимо, из водорода и (C1-C6)алкила, или R6 и R7, или R8 и R9, вместе с атомом азота, к которому они присоединены, образуют пирролидиновое, пиперидиновое ...

DERIVATIVES WITH A URONIC ACID STRUCTURE, THEIR PREPARATION AND THEIR BIOLOGICAL APPLICATIONS

Verfahren zur Herstellung von oxydierter Staerke

Process for producing uronic acids

The yield of uronic acids in the acid hydrolysis of pectins, pectic acid and polymerized uronic acid compounds is increased by addition to the mixture of hydrolysing acid and pectin, pectic acid or polymerized uronic acid compound a water-soluble salt of a polyvalent metal of variable valency in which the metallic ion is in reduced form. The salt is said to act as an inhibitor by preventing the degradation of the uronic acid formed to furfural, carbon dioxide and water. The hydrolysis is preferably carried out at 109-142 DEG C. and 5-40 lb. gauge pressure for approximately 5-60 minutes. It is preferred to use a mineral acid such as hydrochloric, sulphuric, sulphurous, nitric or phosphoric for the hydrolysis, but organic acids such as oxalic, lactic, citric trichloracetic or monochloracetic may also be used. The preferred inhibitors are the water-soluble salts, such as chlorides, sulphates, phosphates and oxides, of the following metallic ions: cobaltous, nickelous, cuprous, manganous, stannous ...

Novel dihydroxytetrahydropyran compounds, their preparation and use

The invention comprises dihydroxytetrahydropyran compounds of the general formula wherein each R represents a hydrogen atom or a C1 to C3 alkyl group and X represents -CHO, -CH2OH, -CO2H or -CO2R1, wherein R1 is a C1 to C18 saturated or olefinically unsaturated aliphatic hydrocarbyl group. They are prepared by the hydroxylation, preferably with hydrogen peroxide in the presence of tungstic acid, of a 3, 4 dihydro-1, 2-pyran of the general formula or by the conversion of one X group into another. The compounds of the invention may be polymerized by heating to form polyhemiacetals, i.e. a polymer of formula when X is -CHO, of formula when X is -CO2H, of formula when X is -CO2R1 and of the Formula V wherein the CO2R1 group is replaced by CH2OH when X is -CH2OH; x being an integer greater than one. If desired the above polymers can be cross-linked with, for example, polycarboxylic acids or polyisocyanates ...

Derivatives of etoposide and analogs, and pharmaceutical compositions containing them.

Derivatives of etoposide and analogs, and pharmaceutical compositions containing them

The invention relates to compounds having the following formula (I), in which: Ra represents a sugar moiety, an arylamino group, or an alkyl group comprising at least one amino group, Rb represents an halogen atom, an halogenoalkyl group, a nitro group, or a group -NR(COR') in which R and R', independently from each other, represent an alkyl group, R1 represents H, or a protecting group for COOH group, R2, R3, and R4, independently from each other, represent H, or a protecting group for OH group. The invention also relates to the use of such compounds in pharmaceutical compositions for the treatment of cancers.

Derivatives of etoposide and analogs, and pharmaceutical compositions containing them.

HYALURONSÄURE OLIGOSACCHARID PARLIAMENTARY GROUPS AND MEDICINES, THIS CONTAINING

PROCEDURE FOR THE PRODUCTION OF A MIXTURE OF OXIDATION PRODUCTS OF THE SACCHAROSE AND THEIR USE.

GALAKTURONSÄUREDERIVATE, PROCEDURE FOR YOUR PRODUCTION AND YOUR USE

PROCEDURE FOR THE SELECTIVE OXIDATION OF PRIMARY ALCOHOLS OF OLIGOSACCHARIDEN

PROCEDURES FOR THE PRODUCTION OF DI AND HIGH-OXIDIZED CARBONIC ACIDS OF COAL HYDRATES, COAL HYDRATE DERIVATIVES OR PRIMARY ALCOHOLS

CATALYTIC PROCEDURE FOR THE MODIFICATION OF COAL HYDRATES, ALCOHOLS, ALDEHYDES OR POLYHYDROXYVERBINDUNGEN

PROCEDURE FOR THE PRODUCTION OF POLYGULURONSÄUREN

METHOD FOR PRODUCING MONOMER URONIC ACIDS, ESPECIALLY D- MANNURONIC ACID AND D-GULURONIC ACID AND DERIVATIVES THEREOF, AND THE USE OF THE SAME AS MEDICAMENTS

Sugar derivatives of hydromorphone, dihydromorphine and dihydroisomorphine, compositions thereof and uses for treating or preventing pain

DETECTION OF OLIGOSACCHARIDES IN PATIENT SAMPLES TREATED WITH A GLYCOSAMINOGLYCAN LYASE

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.

WATER-SOLUBLE DERIVATIVES OF SODIUM MANNOHEPTONATE

PROCESS FOR SELECTIVE OXIDATION OF PRIMARY ALCOHOLS

Primary alcohols, especially in carbohydrates, can be selectively oxidised to aldehydes and carboxylic acids in a low-halogen process by using a peracid in the presence of a catalytic amount of a di-tertiary-alkyl nitroxyl (TEMPO) and a catalytic amount of halide. The halide is preferably bromide and the process can be carried out at nearly neutral to moderately alkaline pH (5-11). The peracid can be produced or regenerated by means of hydrogen peroxide or oxygen. The process is advantageous for producing uronic acids and for introducing aldehyde groups which are suitable for crosslinking and derivatisation.

OXIDATION OF URONIC ACIDS TO ALDARIC ACIDS WITH A GOLD CATALYST UNDER ACIDIC CONDITIONS

Disclosed is the oxidation of uronic acids, such as galacturonic acid, to the corresponding aldaric acids, such as galactaric acid, under neutral or acidic conditions. Use is made of a supported gold catalyst. The oxidation occurs in good selectivity and yield, under unexpectedly mild conditions. A source of galacturonic acids is pectins, such as from sugar beet pulp.

SYNTHETIC HEPARIN PENTASACCHARIDES

Preparation of synthetic monosaccharides, disaccharides, trisaccharides, tetrasaccharides and pentasaccharides for use in the preparation of synthetic heparinoids.

SYNTHETIC HEPARIN PENTASACCHARIDES

Preparation of synthetic monosaccharides, disaccharides, trisaccharides, tetrasaccharides and pentasaccharides for use in the preparation of synthetic heparinoids.

CATALYTIC OXIDATION OF URONIC ACIDS TO ALDARIC ACIDS

Disclosed is the oxidation of uronic acids, such as galacturonic acid, to the corresponding aldaric acids (characterized by the formula HOOC-(CHOH)n-COOH, with n being an integer of from 1 to 5) such as galactaric acids. The starting material comprising the uronic acid is subjected to oxygen under the influence of a supported gold catalyst and in the presence of a base. The oxidation occurs in good selectivity and yield, under unexpectedly mild conditions. A source of galacturonic acids is pectin, such as that derived from sugar beet pulp.

PRODUCTION OF SACCHARIDE CARBOXYLIC ACIDS

A process for producing a saccharide carboxylic acid or a salt thereof characterized in that a microorganism belonging to the genus Pseudogluconobacter and capable of oxidizing a hydroxymethyl group and/or hemiacetal hydroxyl-associated carbon atom to a carboxyl group, or an artifact derived from the microorganism, is permitted to act on a hydroxymethyl and/or hemiacetal hydroxyl-containing saccharide or saccharide derivative to produce and accumulate the corresponding carboxylic acid and the carboxylic acid so accumulated is harvested and novel saccharide carboxylic acids produced by the above production method, and by the process, from a broad range of saccharides, saccharic acids having carboxyl groups derived from hydroxymethyl and/or hemiacetal OH groups can be produced with high selectivity and in good yield, the resultant saccharide acids are resistant to enzymatic degradation and have improved water solubility, among other characteristics.

N-METHYLDEACETYLCOLCHICEINAMIDE DERIVATIVES

Abstract of the Disclosure N-methyldeacetylcolchiceinamide derivatives represented by the formula wherein R denotes a residue obtained by remov-ing COOH from a C3-C7 sugar carboxylic acid, and hydroxyl groups present in the residue may properly be protected with a protecting group for a hydroxyl group. Said N-methyldeacetylcolchiceinamide derivatives have less toxicity and strong effect for inhibiting prolifera-tion of tumor cells, and are expected to be used as a carcinostatic.

Verfahren und Vorrichtung zur Durchführung elektrolytischer Reduktionen.

Procédé de fabrication de l'acide galacturonique

Verfahren zur Herstellung eines Salzes eines neuen Polyschwefelsäureesters.

Verfahren zur Herstellung von Polyschwefelsäureestern von Polygalakturonsäuremethylestern.

Verfahren zur Herstellung von Glucuronsäure oder Glucuronolacton

N1-Glucuronosido-N2-isonicotinoyl-hydrazin-alkali- und -erdalkalimetallsalzen

Verfahren zur Herstellung von Metallsalzen der Glucuronsäure

PROCEDURE FOR THE PRODUCTION OF ESSENTIAL METAL ION COMPLEXES OF OLIGO AND/OR POLYGALAKTURONSAEUREN.

Pharmaceutical composition for the treatment of vascular disorders affecting the extremities

TsIKLOPENTENONY, METHODS OF THEIR SYNTHESIS AND USE

INDUCING APOPTOSIS OF PRODUCT AND METHOD FOR ITS PRODUCTION, INDUCTOR OF APOPTOSIS AND METHOD OF INDUCTION OF APOPTOSIS, INDUCTOR FOR DIFFERENTIATION OF CARCINOGENIC CELLS, FOOD PRODUCT, PHARMACEUTICAL COMPOSITIONS AND HYGIENIC AGENT

ПРОЦЕССЫ ПОЛУЧЕНИЯ ОРГАНИЧЕСКОЙ СОЛИ ИЛИ ОРГАНИЧЕСКОЙ КИСЛОТЫ ИЗ ВОДНОГО САХАРНОГО ПОТОКА

Предложен процесс получения, по крайней мере, одной или более, чем одной соли органической кислоты (или кислот) или органической кислоты (или кислот) из водного сахарного потока, который содержит одну или более, чем одну неорганическую кислоту и органическую кислоту (или кислоты). Процесс включает в себя введение водного сахарного потока в сепарационное устройство, которое содержит один или более слой анионообменной смолы и получение из него потока, который содержит сахар. После этого слой или слои анионообменной смолы регенерируют в одну или более стадий, получая, по крайней мере, один поток продукта, который содержит органическую кислоту, соль органической кислоты или их комбинацию и отдельный исходный поток, который содержит неорганическую кислоту, соль неорганической кислоты или их комбинацию. Поток продукта после этого выделяют. Разделение может проводиться в двух сепарационных блоках или с помощью одного анионообменного блока.

Remedy for nerve damage

Improved station for sewage purification

COMPLEXES Of ACIDS OLIGOGALACTURONIQUES AND POLYGALACTURONIQUES FORMS WITH ESSENTIAL METAL IONS

A process for preparing alkali metal salts of glucuronic acid from glucuronolactone

PENTASACCHARIDES SUBSTITUES POSSEDANT DES PROPRIETES BIOLOGIQUES, LEUR PREPARATION ET LEURS APPLICATIONS EN TANT QUE MEDICAMENTS

PENTASACCHARIDES A STRUCTURE (D-GLUCOSAMINE)-(ACIDE GLUCURONIQUE)-(D-GLUCOSAMINE)-(ACIDE L-IDURONIQUE)-(D-GLUCOSAMINE) POSSEDANT UNE ACTIVITE ANTI-XA (YIN-WESSLER) ELEVEE. CES PRODUITS SONT UTILISABLES NOTAMMENT COMME MEDICAMENTS ANTI-THROMBOTIQUES.

Antithrombotic oligosaccharide fragments of muco-polysaccharide prodn. - by reacting uronic acid and glucosamine units

Antithrombotic oligosaccharide fragments of muco-polysaccharide prodn. - by reacting uronic acid and glucosamine units

New disaccharides composed of units having a D-glucosamine and L-iduronic acid structure and method for preparing them

Antithrombotic oligosaccharide fragments of muco-polysaccharide prodn. - by reacting uronic acid and glucosamine units

16.2.82, 28.5.82, 22.6.82(2), 2.7.82 6.8.82, 20.9.82(2)-FR-001575, 002526, 009392 010891/2, 011679, 013804, 015803/4) Prodn. of oligosaccharides (I) contg. or corresponding to fragments of acidic mucopolysaccharides comprises reacting two cpds., consisting of (or terminated by) units A of glucosamine (esp. in the D form) and of units U of glucuronic acid (esp) or iduronic acid (esp. L). One of units A and U is an alcohol with the hydroxy gp. at 3,4 or 6 position (for A) or at 2,3 or 4 position (for U), while the other has an activated anomeric carbon, i.e. an atom carrying a gp. reactive with hydroxy to form a glycosyl ether bond. All atoms (except the activated one) carry protected hydroxy, amino, or carboxy gps.(or their precursors) and it is esp. pref. that several different protecting gps. are used. This allows various substits. to be introduced subsequently at various positions. Formation of the disaccharide (2-N-sulphate or (2-N-acetyl)-6-O-sulphate-D-glucosamine) (methyl D-glucuronic acid). Intermediate oligosaccharides formed in the process and similar cpds. in which 1-3 hydroxy gps. are deprotected during the reaction are new. (I) are esp. useful as antithrombotic agents and also as biological reactants. The process is very generally applicable, and gives very pure prods. with the required stereospecificity.

MONOGLYCOSIDE ACID PURIFICATION METHOD

The invention discloses a purifying method of monoglycoside acid which comprises selective oxidizing primary hydroxy group of the monoglycoside, exchanging the reacted composite liquid through an activated strong acid cation exchange resin bed and then eluting the ion exchange bed through purified water as elution. The invention separates the monoglycoside acid from inorganic salt effectively, the separated monoglycoside acid can be directly applied to manufacture monoaldonic acid lactone.

KETOALDONIC ACIDS HAVING FORMED STEREOGENIC CENTERS OF R CONFIGURATION: METHODS AND COMPOSITIONS

The present invention provides a ketoaldonic acid such as an octulosonic or nonulosonic acid having formed stereogenic center of R configuration, as well as methods of synthesizing the same.

Geranyl compounds

This invention provides compounds having excellent antitumor activity, which are represented by the following formulae in which R1, R2, R3, m, n and R4 have the significations as given in the specification.

PROCESS FOR SELECTIVE OXIDATION OF PRIMARY ALCOHOLS

СПОСОБ ПОЛУЧЕНИЯ D-ГЛЮКУРОНОВОЙ КИСЛОТЫ

FIELD: organic chemistry, chemical technology. SUBSTANCE: invention relates to method for preparing D-glucuronic acid by heating 1,2-O-isopropylidene-D-glucuronic acid salts in water-containing solution in the presence of acidic agents. Sulfoacid cation-exchange resins are used as acidic agents with exchange capacity 4 mg-eq/g, not less, taken in the amount 0.5 g per 0.001 mole of 1,2-O-isopropylidene-D-glucuronic acid salts, not less. Heating 1,2-O-isopropylidene-D-glucuronic acid salts is carried out at temperature 40-95 C using ethanol aqueous solution with concentration 50%, not above, as a water-containing solution. Salts with alkaline or alkaline-earth metals or ammonium salts are used as 1,2-O-isopropylidene-D-glucuronic acid salts. Invention provides ecological safety of method and improvement of end product purity. EFFECT: improved preparing method. 5 cl, 6 ex 2211841 С1 Ко РОССИЙСКАЯ ФЕДЕРАЦИЯ (19) (13) (11) < > аа ЗА СЛ \ * © < \ ВО ет Зо \ 51) МК’ © 07 Н 7/033 ФЕДЕРАЛЬНАЯ СЛУЖБА ПО ИНТЕЛЛЕКТУАЛЬНОЙ СОБСТВЕННОСТИ, ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (12) ИЗВЕЩЕНИЯ К ПАТЕНТУ НА ИЗОБРЕТЕНИЕ (21), (22) Заявка: 2002108340/04, 02.04.2002 (72) Автор(ы): Белянин М.Л., (24) Дата начала отсчета срока действия патента: Гольдберг Е.Д.., 02.04.2002 Дыгай А.М. Филимонов В.Д.., (46) Опубликовано: 10.09.2003 Хазанов В.А. (56) Список документов, цитированных в отчете о поиске: 1. ФЕЛЬДМАН Д.П.и др. Способ получения О-глюкуроната натрия. Хим.-Фарм. Журнал, 1984, № 11, с. 1356-1360. 2. $0 883054 А, 23.11.1981. 3. $Ч 1018951 А, 23.05.1983. 4.СВ 670928 А, 30.04.1952. (73) Патентообладатель(и): Общество с ограниченной ответственностью "Макферон" Адрес для переписки: 634050, г. Томск, а/я 86, пат.пов. Л.В.Бутенко (54) СПОСОБ ПОЛУЧЕНИЯ О)-ГЛЮКУРОНОВОЙ КИСЛОТЫ Опубликовано на СО-КОМ: ММОЗА КВЕО 2003009 МКЕО2003009 РСАА - Регистрация договора об уступке патента СССР или патента Российской Федерации на изобретение (21) Регистрационный номер заявки: 2002108340 Прежний патентообладатель: ...

VERFAHREN ZUR HERSTELLUNG VON C-GLYKOSIDEN DER ULOSONSÄURE

Verfahren zur Herstellung eines Glucuronsaeuresalzes

Glycolipid derivatives

OLIGO- AND POLYGALACTURONIC ACID COMPLEXES FORMED WITH ESSENTIAL METAL IONS

PROCEDURE AND DEVICE FOR THE PRODUCTION OF MONO CARBONIC ACIDS OF COAL HYDRATES, COAL HYDRATE DERIVATIVES OR PRIMARY ALCOHOLS

DEACETYLCOLCHICINDERIVATE.

SUGAR DERIVATIVES OF HYDROMORPHON, DIHYDROMORPHIN AND DIHYDROISOMORPHIN, COMPOSITIONS OF IT AND USE FOR PREVENTION AND TREATMENT OF PAIN

SACCHAROSE TRI CARBONIC ACID AND THEIR DERIVATIVES, PROCEDURES FOR THE PRODUCTION OF SACCHAROSE TRI CARBON|URE AND YOUR SALTS AND YOUR USE.

PROCEDURE FOR SELECTIVE OXIDIZING OF PRIMARY ALCOHOLS

Geranyl compounds

SYNTHETIC HEPARIN PENTASACCHARIDES

Cyclopentenones, process for preparing the same, and the use thereof

A METHOD OF OXIDISING CARBOHYDRATES

5-OXO-2,4-DICHLORO-4-SUBSTITUTED PENTANENITRILES

Method for the oxidation of aldehydes, hemiacetals and primary alcohols

SUCROSETRICARBOXYLIC ACID

Imaging agents and methods of use

An imaging agent and a method of its use for imaging a necrosis in a tissue of a subject. The imaging method may be positron emission tomography (PET). In at least one embodiment the imaging agent comprises 2-deoxy-2-[ ...

DERIVES A STRUCTURE ACIDE URONIQUE, LEUR PREPARATION ET LEURS APPLICATIONS BIOLOGIQUES

... "Nouveaux dérivés à structure acide uronique leur préparation et leurs applications biologiques" Les dérivés d'acide uronique de l'invention répondent à la formule (III) dans laquelle les substituants -OR1 à -OR6 sont choisis parmi un groupe réactif, un groupe fonctionalisable ou correspondent à des fonctions -OH bloquées par des groupements protecteurs. Ces dérivés sont utilisables pour préparer des glycosides d'intérêt biologique, en particulier des substrats d'enzymes. Pas de figure ...

DISACCHARIDES FOR THE TREATMENT OF TENDONS, LIGAMENTS AND BONES

The present invention relates to the use of a series of disaccharides, as well as of compositions containing them, for the preparation of a medicament for the treatment or prevention of a tendon, ligament or bone disease, disorder or injury. The present invention also relates to the new compositions comprising a disaccharide in combination with inulin polysulphate, a glycosaminoglycan, a growth factor or cells. The glycosaminoglycan is preferably chondroitin sulphate or hyaluronic acid and the growth factor is IFG-1.

GERANYL COMPOUNDS

This invention provides compounds having excellent antitumor activity, which are represented by the following formula (see formula I-3) in which R3 stands for p-hydroxylphenyl or mercapto group.

METHOD OF PRODUCING OLIGOMANNURONOVYKh DIACIDS

APOPTOSIS INDUCING PRODUCT AND METHOD FOR MANUFACTURING SAME, APOPTOSIS INDUCER AND METHOD OF APOPTOSIS INDUCING, INDUCER FOR DIFFERENTIATION OF CANCEOUS CELLS, FOOD PRODUCT, PHARMACEUTICAL COMPOSITIONS AND HYGIENIC MEANS

1. An apoptosis inducing product obtained by heating at a temperature from room to 350 degree C for several seconds to several days under acidic to neutral conditions at least one substance selected from the following (a), (b) and (c): (a) uronic acid or uronic acid derivative; (b) a saccharide compound containing uronic acid or a saccharide compound containing uronic acid derivative; and (c) a substance containing a saccharide compound containing uronic acid or a substance containing a saccharide compound containing uronic acid derivative. 2. A product according to claim 1 wherein uronic acid is galacturonic acid, glucuronic acid, guluronic acid, mannuronic acid and/or iduronic acid. 3. A product according to claim 1 wherein the derivative is uronic acid lactone, uronic acid ester, uronic acid amide or salt thereof. 4. A heat-treated product according to claim 1 wherein the saccharide compound is a saccharide compound which is selected from pectin, pectic acid, alginic acid, hyaluronic acid, heparin, fucoidan, chondroitin sulfate, chondroitin, dermatan sulfate and/or decomposed product thereof. 5. A product according to any of claims 1-4 wherein the heat-treated product is obtained by heating at 60-350 degree C for several seconds to several days. 6. A heat-treated product according to any of claims 1-5 wherein the heat-treated product is a product obtained by means of a molecular weight fractionation. 7. A food product which is characterized in containing the heat-treated product mentioned in any of claims 1-6. 8. A food product having an anticancer action which is characterized in containing the heat-treated product mentioned in any of claims 1-6. 9. Antibacterial agent which is characterized in containing any of the heat-treated product mentioned in any of claims 1-6. 10. Antiseptic agent which is characterized in containing the antibacterial agent of claim 9. 11. Dentifrice which is characterized in containing the antibacterial agent of claim 9. 12. An ...

METHOD FOR PREPARING OLIGOMERIC MANNURONIC DIACID

ЦИКЛОПЕНТЕНОНЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЕ

... 1. Способ получения 4,5-дигидрокси-2-циклопентен-1-она, представленного формулой [1] заключающийся в том, что по меньшей мере одно вещество, выбранное из следующих: (a), (b) и (c), подвергают нагреванию, где (a) уроновая кислота или производное(производные) уроновой кислоты; (b) сахаридное производное, содержащее уроновую кислоту и/или производное(производные) уроновой кислоты; и (c) вещество, содержащее сахаридное производное, которое содержит уроновую кислоту и/или производное(производные) уроновой кислоты. 2. Способ получения 4,5-дигидрокси-2-циклопентен-1-она, заключающийся в том, что по меньшей мере одно вещество, выбранное из следующих: (a), (b) и (c), подвергают нагреванию и 4,5-дигидрокси-2-циклопентен-1-он, представленный формулой [1] выделяют из вышеуказанного термообработанного продукта, где (a) уроновая кислота или производное(производные) уроновой кислоты; (b) сахаридное производное, содержащее уроновую кислоту и/или производное(производные) уроновой кислоты; и (c) вещество ...

АНТИБАКТЕРИАЛЬНОЕ СРЕДСТВО И АНТИСЕПТИК, СРЕДСТВО ДЛЯ ЧИСТКИ ЗУБОВ, КОСМЕТИЧЕСКОЕ СРЕДСТВО, СРЕДСТВО ДЛЯ ВАНН, ПИЩЕВОЙ ПРОДУКТ ИЛИ НАПИТОК НА ЕГО ОСНОВЕ

1. An antibacterial compound, containing 4,5-dihydroxy-2-cyclopenten-1-one represented by the formula [1]: and/or an optically active derivative thereof. 2. An antiseptic, which is characterized in containing the antibacterial agent according to Claim 1 as effective ingredient(s). 3. A dentifrice, which is characterized in containing the antibacterial agent according to Claim 1 as effective ingredient(s). 4. A cosmetic, which is characterized in containing the antibacterial agent according to Claim 1 as effective ingredient(s). 5. A bathing agent, which is characterized in containing the antibacterial agent according to Claim 1 as effective ingredient(s). 6. An antibacterial food, which is food, comprising antibacterial compound of Claim 1. 7. An antibacterial beverage, which is beverage, comprising antibacterial compound of Claim 1.

NOUVEAUX DERIVES D'OSIDES ET LEUR PREPARATION

L'INVENTION CONCERNE DES OSIDES CONSTITUES PAR DES DISACCHARIDES A14 FORMES DE DEUX MOTIFS RESPECTIVEMENT A STRUCTURE ACIDE L-IDURONIQUE ET D-GLUCOSAMINE. CES COMPOSES CONSTITUENT NOTAMMENT DES INTERMEDIAIRES EN SYNTHESE OSIDIQUE.

Process and device being used to carry out electrolytic reductions

NOUVEAU MEDICAMENT UTILE NOTAMMENT COMME DIURETIQUE ET DETOXICANT, DERIVE DE L'ACIDE GALACTURONIQUE

LE MEDICAMENT SELON L'INVENTION CONSISTE EN LE GALACTURONATE DE METHYLE, REPONDANT A LA FORMULE: (CF DESSIN DANS BOPI) CE MEDICAMENT EST UTILE NOTAMMENT COMME DIURETIQUE ET DETOXICANT, LA DOSE JOURNALIERE PAR VOIE ORALE ETANT D'ENVIRON 10 A 30G ET PAR VOIE INTRAMUSCULAIRE DE L'ORDRE DE 1 A 3G.

PROCESSES Of OBTAINING OLIGO-MANNURONATES AND GULURONATES, the PRODUITSOBTENUS AND THEIR USES

PROCESS OF PRODUCTION AND USE OF FAMILIES Of OLIGOMERS Of GALACTURONIC ACID.

Uronic acid derivs. - useful as glycoside intermediates or hapten(s)

Process for the preparation of new sulphuric polyesters and their salts

NOUVEAUX TRISACCHARIDES A STRUCTURE D-GLUCOSAMINE, ACIDE L-IDURONIQUE, D-GLUCOSAMINE ET LEUR PREPARATION

L'INVENTION A POUR OBJET DE NOUVEAUX TRISACCHARIDES DE FORMULE:DANS LAQUELLE: R, R, R ET R REPRESENTENT UN ATOME D'HYDROGENE, UN GROUPE SULFATE, OU UN GROUPE PROTECTEUR; R, R, R ET R REPRESENTENT UN ATOME D'HYDROGENE OU UN GROUPEMENT PROTECTEUR; R REPRESENTE UN GROUPE ALCOYLE, NOTAMMENT DE 1 A 3ATOMES DE CARBONE, EN PARTICULIER LE GROUPE METHYLE, OU UN CATION METALLIQUE TEL QUE LE SODIUM, OU ORGANIQUE TEL QU'UN DERIVE DE BASE ORGANIQUE AZOTE; LES RADICAUX Z, IDENTIQUES OU DIFFERENTS, REPRESENTENT UN GROUPE FONCTIONNEL AZOTE, OU UN GROUPE AZIDE, OU AMINE OU -NHSO.

Alkylgalactosides uronates of alkyl, their method of preparation and their applications, in particular commeagents surface-active nonionic

Les alkylgalactosides uronates d'alkyle de formule: (CF DESSIN DANS BOPI) R1 étant alkyle linéaire ou ramifié ayant de 2 à 22 atomes de carbone, sont des agents tensio-actifs.

Method of preparation of derived from the glucuronic acid

PROCEDE DE PREPARATION DE MONOSACCHARIDES A STRUCTURE ACIDE L-IDURONIQUE

PREPARATION DE MONOSACCHARIDES DE STRUCTURE ACIDE L-IDURONIQUE A PARTIR D'A-D-GLUCOFURANOSIDES PAR PASSAGE DE LA STRUCTURE D-GLUCO A LA STRUCTURE L-IDO ET DE LA STRUCTURE ALCOOL PRIMAIRE A LA STRUCTURE ACIDE CARBOXYLIQUE. CES MONOSACCHARIDES CONSTITUENT NOTAMMENT DES INTERMEDIAIRES EN SYNTHESE OSIDIQUE.

Process for the synthesis and new derivatives of alpha -L-iduronic acid

METHOD FOR PREPARING A COMPOSITION OF GLUCURONIC ACID OR A GLUCURONIC ACID DERIVATIVE COMPRISING A OXIDATION STAGE ELECTRONIC

La présente invention a pour objet un procédé de préparation d'une composition d'acide glucuronique ou d'un dérivé d'acide glucuronique caractérisé en ce qu'il comprend une étape au cours de laquelle on soumet une composition de glucose protégé en C1 à un traitement d'électrooxydation effectué : a) en présence d'un oxyde d'amine, b) dans un réacteur compartimenté, et c) à une température inférieure à 20°C, de préférence inférieure à 16°C et plus préférentiellement encore comprise entre 1 et 14°C.

Preparation of uronic acids and their derivatives

Processo e dispositivo para a preparação de ácidos monocarboxilicos de carboidratoa derivados de carboidratos ou álcoois primários

Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor.

DERIVATIVES OF URONIC (ALKYL-D-MANNOPYRANOSIDE) ACID, METHODS FOR THE PREPARATION THEREOF, AND APPLICATIONS THEREOF

Disclosed are derivatives of general formula (I), in which x equals zero or one, R1 represents -(CH2)n-CH3, n ranging between 3 and 21, R2 and R3, which can be identical or different, represent one or another of the following substituents: O-(CH2)m-CH3, m ranging between 3 and 21; OH; OM, M representing an alkali or alkaline-earth metal cation; NH-(CH2)p-CH3, p ranging between 3 and 11; NH-(CH2)q-NH2, q ranging between 4 and 22; NH-(CH2)r-NH-CO-CH2-N(CH3)3 CI, r ranging between 4 and 22; NH-(CH2)s-NH-CO-sugar, s ranging between 4 and 22, and the salts thereof.

METHODS FOR OBTAINING OLIGOMANNURONATES ET GULURONATES, PRODUCTS OBTAINED AND USE THEREOF

The invention relates to a method for obtaining saturated or unsaturated oligo-mannuronates, characterized in that it consists in carrying out the following steps : a) brown algae are dispersed in an acidic medium in a heated state, having a pH of less than or equal to 2; b) the insolube fraction is separated by filtering from the soluble fraction obtained in step a), said insoluble fraction containing algal cellulose from said algae and the A-L guluronic (G) and B-D-mannuronic (M) blocks; the pH of said insoluble fraction is adjusted to approximately 2.8 by adding a base; d) the insoluble fraction is separated by filtering from the soluble fraction obtained in step c), said soluble fraction containing B-D mannuronic acid (M) blocks; e) the soluble fraction obtained from step d) is depolymerized acidically or enzymatically or acidically/enzymatically in order to obtain saturated and/or unsaturated oligomannuronates.

DETECTION OF OLIGOSACCHARIDES

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130-. (canceled)31. A method of determining in an individual the presence , identity , and/or severity of an MPS IIIA or MPS IIIB disorder , the method comprising:(a) generating a biomarker comprising one or more saturated non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of heparan sulfate oligosaccharides, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS IIIA or MPS IIIB disorder relative to individuals without the MPS IIIA or MPS IIIB disorder; and(b) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence of and/or measure of the amounts of the biomarker are utilized to determine the presence, identity, and/or severity of the MPS III disorder; andwherein the biomarker is selected from a group consisting of{'sub': '3', 'Formula III: [GlcNS-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula IV: [GlcNS-GlcA-GlcN(Ac)0-1](SOR)0-2;'}{'sub': '3', 'Formula V: [GlcNAc-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula VI: [GlcNAc-GlcA-GlcN(Ac)0-1](SOR)0-2;'}{'sub': '3', 'Formula VIII: [GlcN-GlcA-GlcN(Ac)0-1](SOR)0-4;'}{'sub': '3', 'Formula IX: [GlcNAc6S-IdoA-GlcN(Ac)0-1](SOR)0-3;'}{'sub': '3', 'Formula X: [GlcNAc6S-GlcA-GlcN(Ac)0-1](SOR)0-2;'}GlcN-IdoA-GlcNAc;GlcN-IdoA2S-GlcNAc;GlcN-IdoA-GlcNS;GlcN-IdoA-GlcNAc6S;GlcN-IdoA2-GlcNAc6S; andGlcN-IdoA-GlcNS6S.32. The method of claim 31 , wherein the biomarker is of Formula V: [GlcNAc-IdoA-GlcN(Ac)-1](SOR); or ...

NEW CLASS OF SUCROSE ESTERS AND A METHOD FOR THEIR PREPARATION

The present invention relates to a new class of sucrose esters and a method for their preparation. 1B. megaterium. A method for the preparation of a P-D-fructofuranosyl-(2 ,1)-α-D-uronic acid or an ester thereof which comprises the step of fructosvlating a D-uronic acid salt or ester thereof in the presence of levansucrase (Bm-Ls).2. The method claim 1 , wherein the D-uronic acid is D-galacturonic acid or D-glucuronic acid.3. The method of claim 1 , wherein the D-uronic acid salt is an alkali metal salt.4. The method of claim 1 , residue having 1 to 30 carbon atoms which may be interrupted by one or more heteroatoms and which may be substituted by one or more functional groups.5. The method of claim 1 , wherein the method is for the preparation of a β-D-fructofuranosyl-(2 claim 1 ,1)-α-D-uronic acid ester claim 1 , further wherein an esterificaiton step is conducted prior or after the fructosylation step.6. The method of claim 5 , wherein the esterification step is conducted in the presence of tetrabutylammonium fluoride.7. A method for the preparation of a D-uronic acid ester comprising the step of reacting D-uronic acid with an organic halide in the presence of tetrabutylammonium fluoride.8. The method of claim 7 , wherein the organic halide has the formula Hal-R claim 7 , wherein R is a hydrocarbon residue having 1 to 30 carbon atoms which may be interrupted by one or more heteroatoms and which may be substituted by one or more functional groups.9. The method of claim 7 , wherein the halide is I.10. β-D-fructofuranosyl-(2 claim 7 ,1)-α-D-uronic acid mono ester.11. β-D-fructofuranosyl-(2 claim 7 ,1)-α-D-galacturonic acid.12. β-D-fructofuranosyl-(2 claim 7 ,1)-α-D-6-p-toluensulfonylglycopyranoside.13. β-D-fructofuranosyl-(2 claim 7 ,1)-α-D-6-azidoglycopyranoside.14. The method of claim 3 , wherein the alkali metal salt is sodium salt. The present invention relates to a new class of sucrose esters and a method for their preparation.Carbohydrates are an important ...

Method for preparing surfactant compositions comprising alkyl liduronamides d-glucuronamides and l-rhamnosides from ulvans

The present invention relates to a novel process for preparing surfactant compositions based on alkyl L-iduronamides, alkyl L-rhamnosides and alkyl D-glucuronamides, to the compositions obtained via said process and to the uses thereof.

METHOD FOR PREPARING OLIGOMERIC MANNURONIC DIACID

The invention relates to a new method of preparing oligomannuronic diacids, important bioactives. The method utilizes oligomannuronic acids as starting materials and the target substances are obtained by acid degradation and active hypobromous acid oxidation steps. The method of preparing oligomannuronic diacids according to the invention employs moderate reaction conditions, has few side reactions, does not need further purification, achieves a yield of more than 90%, or even more than 95%, and is suitable for production with an on-line continuous reactor device, with reaction processes easy to implement automatic control. 1. A method of preparing oligomannuronic diacids , comprising an oxidation reaction step of contacting oligomannuronic acids with a bromine-containing oxidant.2. The method of claim 1 , wherein the bromine-containing oxidant is selected from the group consisting of bromine water claim 1 , liquid bromine claim 1 , hypobromous acid claim 1 , hypobromite claim 1 , a combination of a bromide ion source with hypochlorite claim 1 , and a combination of bromine with hypochlorite.3. The method of claim 1 , wherein the molar amount of the bromine-containing oxidant calculated based on hypobromous acid and/or hypochlorite is 1.0-2.0 folds of the reaction raw material oligomannuronic acid.4. The method of claim 1 , wherein the temperature of the oxidation reaction is 10-40° C.5. The method of claim 1 , wherein the pH of the oxidation reaction is controlled to be between 6.5 and 9.5.6. The method of claim 2 , wherein the hypobromous acid or hypobromite is obtained by in situ production.7. The method of claim 6 , wherein the in situ production is achieved by the reaction of bromine with an aqueous alkaline solution.8. The method of claim 1 , wherein the aqueous alkaline solution is an aqueous solution of an alkali metal hydroxide or an alkali metal phosphate or an alkali metal carbonate claim 1 , such as an aqueous solution of sodium hydroxide or sodium ...

DETECTION OF OLIGOSACCHARIDES

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130.-. (canceled)31. A method for determining in an individual , the presence , identity , and/or severity of MPS I disorder , the method comprising:a) generating a biomarker comprising of one or more non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of glycosaminoglycans, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS I disorder relative to individuals without the MPS I disorder; andb) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence and/or the measure of the amount of the biomarker are utilized to determine the presence, identity, and/or severity of MPS I disorder; andwherein the biomarker is selected from a group consisting ofFormula I-A: IdoA-GlcNAc;Formula I-B: IdoA-GlcNS;Formula I-C: IdoA-GlcNS6S;{'sub': 3', 'n, 'Formula XII: [IdoA-GalNAc](SOR), wherein n is 0-2;'}{'sub': 3', 'n, 'Formula XXI: [IdoA-GlcN(Ac)m-IdoA](SOR), where m is 0-1 and n is 0-4;'}{'sub': 3', 'n, 'Formula XXII: [IdoA-GlcN(Ac)m-GlcA](SOR), where m is 0-1 and n is 0-3; and'}{'sub': 3', 'n, 'Formula XXIII: [GlcA-GlcN(Ac)m-GlcA](SOR), where m is 0-1 and n is 0-3.'}32. The method of claim 31 , wherein the biomarker is selected from the group consisting of: Formula I-A: IdoA-GlcNAc; Formula I-B: IdoA-GlcNS; Formula I-C: IdoA-GlcNS6S; and Formula XII: [IdoA-GalNAc](SO3R)n claim 31 , wherein n is 0-2.33. The method of claim 31 , wherein the biomarker is selected from the ...

IMAGING AGENTS AND METHODS OF USE

An imaging agent and a method of its use for imaging a necrosis in a tissue of a subject. The imaging method may be positron emission tomography (PET). In at least one embodiment the imaging agent comprises 2-deoxy-2-[F]fluoroglucaric acid (F-FGA), or a pharmaceutically-acceptable salt thereof. The imaging agent may be disposed in a pharmaceutically-acceptable excipient, carrier, diluent, or vehicle. The imaging agent may be contained within a kit. The disclosure includes in at least one embodiment a method of preparing a radiopharmaceutical such as F-FGA for use in imaging. 1. An imaging agent comprising 2-deoxy-2-[F]fluoroglucaric acid , or a pharmaceutically-acceptable salt thereof.2. A composition comprising the imaging agent of disposed in a pharmaceutically-acceptable carrier claim 1 , diluent claim 1 , vehicle claim 1 , or excipient.3. A method of positron emission tomography (PET) imaging of a subject claim 1 , comprising:{'sup': 18', '18, 'administering to the subject an imaging agent comprising 2-deoxy-2-[F]fluoroglucaric acid (F-FGA), or a pharmaceutically-acceptable salt thereof;'}allowing the imaging agent to penetrate into a tissue of the subject, the tissue suspected to contain a necrosis; andcollecting a PET image of the tissue suspected to contain the necrosis.4. The method of claim 3 , comprising preparing the F-FGA claim 3 , or a pharmaceutically-acceptable salt thereof claim 3 , from a quantity of 2-deoxy-2-[F]fluoro-D-glucose (F-FDG) claim 3 , wherein the administering step occurs within about 3 hours after preparing the F-FGA.5. The method of claim 3 , wherein the subject is suspected of having tissue damage due to a cancer claim 3 , brain stroke claim 3 , traumatic brain injury claim 3 , or myocardial infarction.6. The method of claim 3 , wherein the tissue is selected from a group consisting of tissues of the myocardium claim 3 , brain claim 3 , breast claim 3 , prostate claim 3 , colon claim 3 , kidney claim 3 , spleen claim 3 , limb claim 3 ...

CLASS OF SUCROSE ESTERS AND A METHOD FOR THEIR PREPARATION

The present invention relates to a new class of sucrose esters and a method for their preparation. 1B. megaterium. β--fructofuranosyl-(2 ,1)-α--6-p-toluensulfonylglycopyranoside obtained by fructosylating 6-O-Toluolsulfonyl--glycopyranose in the presence of levansucrase (Bm-Ls).2. P--fructofuranosyl-(2 ,1)-α--6-azidoglycopyranoside.3B. megaterium. β--fructofuranosyl-(2 ,1)-α--6-azidoglycopyranoside obtained by fructosylating 6-tosyl sucrose in the presence of levansucrase (Bm-Ls). This application is a divisional of U.S. application Ser. No. 16/645,380 filed Mar. 6, 2020, which, in turn, corresponds to the U.S. National phase of International Application No. PCT/EP2018/073528, filed Aug. 29, 2018, which, in turn, claims priority to European Patent Application No. 17001445.0 filed Aug. 29, 2017, the contents of which are incorporated by reference herein in their entirety.The present invention relates to a new class of sucrose esters and a method for their preparation.Carbohydrates are an important source of renewable compounds. The disaccharide sucrose (α-D-glucopyranosyl-(1,2) -β--fructofuranoside) is produced in industrial scale of 170×10MT/y. The development of chemical processes from carbohydrates instead of fossil resources became a principal of Green Chemistry. Sucrose esters are one of this examples. They have many applications in food, cosmetics and pharmaceutical industry. Sucrose possesses 8 hydroxyl groups that can be esterified for example with fatty acids with aliphatic tails of 1 to 18 carbons (L. Osipow, F. D. Snell, W. C. York and A. Finchler, , 1956, 48, 1459-1462). The chemical production of sucrose esters has been investigated (L. I. Osipow and W. Rosenblatt, J , 1967, 44, 307-309) but the selectivity in the synthesis of these esters remains a challenge. Lipases from i.e. and catalyze the transesterification to 2-O-acylsucrose or 6-O-acylsucrose. Most are mixtures of double esterification. All these sucrose esters derive from a carboxylic acid ( ...

OXIDIZED A-1,4-OLIGOGLUCURONIC ACID, AND PREPARATION METHOD THEREFOR AND USES THEREOF

An oxidized α-1,4-oligoglucuronic acid, and a preparation method therefor and uses thereof. By using abundant starch, especially soluble starch, in the natural world as the raw material, all 6-site hydroxyl groups of the starch α-1,4-polyglucose are oxidized into carboxyl groups to form glucuronic acid under the action of a sodium bromide (NaBr)-2,2,6,6-tetramethyl piperidine oxide (TEMPO)-sodium hypochlorite (NaClO) oxidation system, and the oxidized oligoglucuronic acid having an open ring at an end is prepared by controlling reaction conditions. The compound has obvious anti-cerebral ischemia activity, and can be developed into a potential anti-cerebral ischemia drug. 2. The oxidized α-1 claim 1 ,4-oligoglucuronic acid of claim 1 , wherein m=0.3. The oxidized α-1 claim 1 ,4-oligoglucuronic acid of claim 1 , wherein m=1.4. The oxidized α-1 claim 1 ,4-oligoglucuronic acid of claim 1 , wherein m=2.5. The oxidized α-1 claim 1 ,4-oligoglucuronic acid of claim 1 , wherein n=1-19.6. The oxidized α-1 claim 1 ,4-oligoglucuronic acid of claim 1 , wherein n=1-9.7. The oxidized α-1 claim 1 ,4-oligoglucuronic acid of claim 1 , wherein n is 1 claim 1 , 2 claim 1 , 3 claim 1 , 4 claim 1 , 5 claim 1 , 6 claim 1 , 7 claim 1 , 8 claim 1 , or 9 claim 1 , each corresponding to disaccharide claim 1 , trisaccharide claim 1 , tetrasaccharide claim 1 , pentasaccharide claim 1 , hexasaccharide claim 1 , heptasaccharide claim 1 , oct-saccharide claim 1 , nonus-saccharide or decasaccharide of the oxidized α-1 claim 1 ,4-oligoglucuronic acid.9. The mixture of claim 8 , wherein n′ is selected from 1.0 to 10.0 and m′ is selected from 0.5 to 1.8.10. The mixture of claim 8 , wherein the components with n of 1-9 account for more than 80% by weight of the mixture.11. A preparation process for oxidized α-1 claim 1 ,4-oligoglucuronic acid of claim 1 , comprising following steps:(1) weighing soluble starch and preparing it into aqueous solution;(2) sequentially adding 2,2,6,6-tetramethylpiperidine ...

DETECTION OF OLIGOSACCHARIDES

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation. 130-. (canceled)31. A method of determining in an individual the presence , identity , and/or severity of an MPS III disorder , the method comprising:(a) generating a biomarker comprising one or more saturated non-reducing end oligosaccharides, wherein the biomarker is generated by treating a population of heparan sulfate oligosaccharides, in or isolated from a biological sample from the individual, with at least one digesting glycosaminoglycan lyase, wherein prior to lyase treatment, the biomarker is not present in abundance in samples from individuals with the MPS III disorder relative to individuals without the MPS III disorder; and(b) using an analytical instrument to detect the presence of and/or measure the amount of the biomarker produced and displaying or recording the presence of or the measure of the biomarker produced;wherein the presence of and/or measure of the amounts of the biomarker are utilized to determine the presence, identity, and/or severity of the MPS III disorder; and{'sub': m', 'n', '3', 'p, 'wherein the biomarker is of Formula II: [GlcN(Ac)-(IdoA/GlcA)-GlcN(Ac)](SOR), wherein (IdoA/GlcA) is IdoA or GlcA; m and n are each independently 0 or 1; p is 0, 1, 2, 3, 4, or 5; and R is hydrogen or a negative charge.'}32. The method of claim 31 , wherein the biomarker is of Formula V: [GlcNAc-IdoA-GlcN(Ac)](SOR) claim 31 , wherein n is 0-1 and p is 0 claim 31 , 1 claim 31 , 2 claim 31 , or 3; or Formula VI: [GlcNAc-GlcA-GlcN(Ac)](SOR) claim 31 , wherein n is 0-1 and p is 0 claim 31 , 1 claim 31 , or 2.33. The method of claim 32 , wherein the biomarker of Formula V is selected from a group consisting of GlcNAc-IdoA-GlcNAc claim 32 , GlcNAc-IdoA2S-GlcNAc claim 32 , GlcNAc-IdoA-GlcNS claim 32 , GlcNAc-IdoA2S-GlcNS ...

OXIDATION OF URONIC ACIDS TO ALDARIC ACIDS

Disclosed is the oxidation of uronic acids, such as galacturonic acid, to the corresponding aldaric acids, such as galactaric acid, under neutral or acidic conditions. Use is made of a supported gold catalyst. The oxidation occurs in good selectivity and yield, under unexpectedly mild conditions. A source of galacturonic acids is pectins, such as from sugar beet pulp. 1. A process for the preparation of an aldaric acid by the oxidation of the corresponding uronic acid , wherein a starting material comprising the uronic acid is subjected to oxygen under the influence of a supported gold catalyst at a pH below 7 , wherein the gold catalyst is a monometallic or bimetallic gold catalyst.2. A process according to claim 1 , wherein the gold catalyst is a bimetallic gold catalyst comprising gold and a metal selected from the group consisting of palladium claim 1 , platinum claim 1 , rhodium claim 1 , ruthenium claim 1 , iridium and osmium.3. A process according to claim 1 , wherein the pH is in a range of from 1-6 claim 1 , preferably 1-4.4. A process according to claim 1 , wherein the pH is the pH naturally occurring during the reaction.5. A process according to claim 1 , wherein the oxygen is in the form of air claim 1 , or in the form of an oxygen-containing gas-stream claim 1 , such as oxygen-enriched air claim 1 , comprising at least 40% oxygen claim 1 , preferably at least 60% oxygen.6. A process according to claim 1 , wherein the uronic acid is selected from the group consisting of galacturonic acid claim 1 , glucuronic acid claim 1 , mannuronic acid claim 1 , guluronic acid claim 1 , and mixtures thereof.7. A process according to claim 1 , wherein the starting material further comprises at least one aldose.8. A process according to claim 6 , wherein the starting material comprises a pectin hydrolyzate claim 6 , preferably sourced from sugar beet pulp.9. A process according to claim 1 , wherein the oxidation is carried out at a temperature in the range of from 20° C ...

METHOD FOR SELECTIVE OXIDATION OF PRIMARY ALCOHOLS

Geranyl compounds

본 발명은 우수한 항종양 활성을 갖는 하기 식 The present invention has the following formula having excellent antitumor activity 식 중 R 1 , R 2 , R 3 , m, n 및 R 4 는 명세서에 기재된 의미를 갖는다 Wherein R 1 , R 2 , R 3 , m, n and R 4 have the meanings described in the specification 로 나타내는 화합물을 제공하는 것이다. It is to provide a compound represented by. 제라닐기 Geranyl

一株大肠埃希氏菌及其在产聚唾液酸中的应用

本发明公开了一株大肠埃希氏菌及其在产聚唾液酸中的应用。本发明自行筛选了一株聚唾液酸生产效率和产量均较高的大肠埃希氏菌，采用该菌株生产聚唾液酸时，不仅能缩短生产时间，降低生产成本，还能得到较高产量的聚唾液酸，具有很好的工业应用前景。

SYNTHETIC AMPHIPHILIC GLYCOCONUGATES FOR NEUROLOGICAL USE.

Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof

本发明公开了用于治疗如抑郁等症状和疾病氟西汀及其类似物的苷、原酸酯苷和糖醛酰胺。

Glycosylation tetravalence platinum-like compounds with active anticancer, preparation method and application

具有抗癌活性的糖基化四价铂类化合物、制备方法及应用，本发明创造首次将糖基基团引入四价铂母核，设计合成了一系列新型糖基化修饰四价铂类化合物，考察了其抗癌、抗肿瘤能力；这一系列原始创新性研究，有望获得对多种对肿瘤有效的先导分子，为解决传统二价铂类药物存在的缺陷提供新候选药物分子，也为四价铂类化合物的修饰开辟新的途径；此类源头上创新药物研究，对国民经济和社会发展及人民健康等都将具有重要的理论价值和实际意义。

Geranyl compounds

본 발명은 우수한 항종양 활성을 갖는 하기 식 The present invention has the following formula having excellent antitumor activity 식 중 R 1 , R 2 , R 3 , m, n 및 R 4 는 명세서에 기재된 의미를 갖는다 Wherein R 1 , R 2 , R 3 , m, n and R 4 have the meanings described in the specification 로 나타내는 화합물을 제공하는 것이다. It is to provide a compound represented by. 제라닐기 Geranyl

Salt of pyranose-substituted heterocyclic compound, preparation method therefor and use thereof

The present application relates to a salt of a pyranose-substituted heterocyclic compound, a preparation method therefor, and use thereof, and in particular, to an acid addition salt of a compound of formula (I) or a prodrug thereof, and further relates to D-glucuronate of a crystalline compound of formula (I) or a prodrug thereof. D-glucuronate of a crystalline compound of formula (II) has particular advantages in terms of crystallizability, subsequent purification, stability, formulation medicinal properties or quality control, and is most applicable for improving the formulation pharmaceutical properties, purity and quality control, as well as large-scale process development of such drugs.

Novel glucuronic acid-gamma-lactone derivatives are useful for the production of liquid crystal compositions

Novel glucuronic acid- psi -lactone derivatives are claimed. Novel glucuronic acid- psi -lactone derivatives (I) are of formula (1). Independent claims are included for: (i) a process for the production of the compounds (I) by reaction of an O<1>-R<3>-D-glucofuranonoic acid-3-lactone with acid halides of formula (4a) or (4b) in an aprotic organic solvent in the presence of a base; and (ii) liquid crystal compositions containing compounds (I). M-Y(A)m-Y-Z (2) T - (X-T)r (3) R<1>COHal (4a) R<2>COHal (4b) R<1>, R<2> = a group of formula (2); R<3> = 1-30C alkyl optionally having -O-, -S-, -NH- or NCH3- linkages in place of non-neighboring methylene groups; M=a mesogenic group of formula (3); T = divalent 6-16C hydrocarbon optionally having -O-, -S- or -NH- groups in place of non-neighboring methylene groups and optionally having one or more methine groups replaced by N=, -NN- groups and optionally substituted by fluorine, bromine, chlorine, cyanide, 1-4C alkyl or 1-4C alkoxy; X = -O-, -COO-, -OCO-, -CH2O-, -CH=N- or a direct bond; Y = a direct bond, -O-, -S-, -COO-, -OCO- or -OCOO-; A = linear 1-30C alkylene optionally having one or more non-neighboring methylene groups replaced by -O-, -S-, -NH- or -NCH3- and optionally substituted by fluorine, bromine, chlorine, cyanide, methyl or ethyl; Z = 3-30C hydrocarbon having at least one polymerizable group comprising vinyl-, alkyl-, cinnamic acid-, epoxy- or bicyclene; m = 0 or 1; r = 0-2.

Product of heat treatment of uronic acid, food, drink or drug including the product

食品、饮料或医药，其特征在于其中含有从：(a)糖醛酸或糖醛酸衍生物，(b)含糖醛酸的糖化合物或含糖醛酸衍生物的糖化合物，(c)含糖醛酸的糖化合物的含有物质或含糖醛酸衍生物的糖化合物的含有物质选出的至少一种物质的热处理产物。

Liposome pH-sensitivity modifier containing menthone 1,2-glycerol ketal and paclitaxel-curcumin compound liposome preparation

本发明涉及一种用于修饰脂质体pH敏感性的修饰剂，其特征在于，由在低分子量透明酸上的D‑葡萄糖醛酸单元连接薄荷酮甘油缩酮而成，其结构式为 其中，n为2‑20。本发明还提供了一种制备所述修饰剂的方法。本发明还提供了一种包含磷脂、胆固醇、药物以及所述修饰剂的pH敏感的脂质体制剂。通过使用本发明的修饰剂，可使所得到脂质体倾向于在低pH的环境下释放内储的药物，并且还孵育脂质体缓释性。

Deacetylcolchicine derivatives, process for preparation thereof, and antitumor composition

FIELD: medicine, as antitumor compound. SUBSTANCE: product: deacetylcolchicine derivative of formula i wherein R is C(O) acyl residue of saccharocarboxylic C 3 -C 7 -acid in which hydroxyl groups may be protected by acyl or ketal group. Reagent 1: deacetylcolchicine. Reagent 2: saccharocarboxylic acid R-COOH. Reaction conditions: amidation conditions. Structure of the compound of formula I: < 939%90с ПЧ Го РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (19) ВИ “” 2 065 863 Сл 57° С 07Н 5/06, А 61 К 31/165, 31/70, 31/195 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 5010441/04, 24.12.1991 (30) Приоритет: 25.12.1990 /Р 413683/90 25.12.1990 УР 419162/90 (46) Дата публикации: 27.08.1996 (56) Ссылки: Машковский М.Д. "Лекарственные средства". М., "Медицина", т.2, с.467, 1986. (71) Заявитель: Охген Рисерч Лабораториз Лтд. (Р) (72) Изобретатель: Киеси Акияма[/Р] (73) Патентообладатель: Охген Рисерч Лабораториз Лтд. (.Р) (54) ПРОИЗВОДНЫЕ ДЕЗАЦЕТИЛКОЛХИЦИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ И ПРОТИВООПУХОЛЕВАЯ КОМПОЗИЦИЯ (57) Реферат: Использование: В качестве противоопухолевого соединения. Сущность: продукт - производное дезацетилколхицина ф-лы | где К-С(О) - ацильный остаток сахарокарбоновой Сз-С7-КиИсСлоты, где гидроксильные группы могут быть защищены ацильной или кетальной группой. Реагент 1: дезацетилколхицин. Реагент 2: сахарокарбоновая кислота К-СООН. Условия реакции: в условиях амидирования. 3 с. и 23. п. ф-лы, 4 табл. Структура соединения ф-лы 1: сн о 3 И Н-С-Е СН_© 3 сн © 3 сн_о 2065863 С1 КО < 939%90с ПЧ Го (19) КУЗЗАМ АСЕМСУ ГОК РАТЕМТ$ АМО ТКАОЕМАКК$ 12) АВЗТКАСТ ОЕ 1МУЕМТОМ ВИ” 2 065 863. (51) 1пЕ. С1.6 13) СЛ С 07 Н 5/06, А 61 К 31/165, 31/70, 31/195 (21), (22) АррИсаНоп: 5010441104, 24.12.1991 (30) РНошу: 25.12.1990 УР 413683/90 25.12.1990 УР 419162/90 (46) Бае ог ричбИсаНоп: 27.08.1996 (71) АррИсапе: Окпадеп ЕР зегсй ГаБбогаюпх Ма. (}Р) (72) |пуетог: Юез АКцата[/Р] (73) Ргорпеюг: Окрдеп Е зегсй Габогаюптх Ма. (рР) (54) РДЕРАСЕТУЕСОЕСНСМЕ ...

Ginseng polysaccharides composition having the use of stabilization and propagation of lactic acid bacteria

본 발명은 인삼 다당체를 함유하는 조성물에 관한 것이다. 상기 조성물은 유산균 동결건조 보호효과, 유산균 보관 안정화 효과, 유산균 증식 효과 및 대장암 등의 원인효소의 생산억제효과가 우수하다. 인삼 다당체, 유산균 동결건조 보호효과, 유산균 보관 안정화 효과, 유산균 증식 효과, 대장암 등의 원인효소의 생산억제효과

Monosaccharide derivatives

Method and installation for production of monocarboxylic acids from carbohydrates, carbohydrate derivatives, or primary alcohols

FIELD: industrial organic synthesis. SUBSTANCE: method involving oxidation of carbohydrates, carbohydrate derivatives, or primary alcohols into monocarboxylic acids which are further isolated electroanalytically is distinguished by that starting materials are oxidized in aqueous solution with weight concentration from 0.1 to 60% with oxygen or oxygen- containing gas in presence of precious metal-based catalysts or mixed metal catalysts based on precious metals and prompters, stream of reaction products being continuously transferred into electroanalysis stage, after which monocarboxylic acids are isolated. Installation contains connected in series gas-passage stage 10, oxidation stage 30, and electroanalysis stage. EFFECT: increased process selectivity. 21 cl, 4 tbl, 7 ex гГучзестс пы ГЭ (19) 13) ВИ "” 2 129 541 ‘Сл 51) МК © 07 С 59/105, 51/235, 51/215 РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 95121941/04, 08.03.1994 (71) Заявитель: Зюдцукер АГ (0Е) (30) Приоритет: 10.03.1993 ОЕ Р4307388.3 (72) Изобретатель: Маркварт Кунц (ОЕ), (46) Дата публикации: 27.04.1999 Ханьо Пуке (ОЕ), Карла Рекер (ОЕ), Линда Шайве (ОЕ), Йорг Ковальчик (ОЕ) (56) Ссылки: ЕР, 0040709 АЛ, 1981. ЗЧ, 109712, АЛ, 1958. ЕР, 0206054, АЛ, 198Г. ЕР, (73) Патентообладатель: <“ 0326673, АЛ, 1989. Зюдцукер АГ (ОЕ) © (85) Дата перевода заявки РСТ на национальную фазу: 10.10.95 = (86) Заявка РСТ: ЕР 94/00695 (08.03.94) < (87) Публикация РСТ: >) М\МУО 94/20448 (15.09.94) © (98) Адрес для переписки: | 103735, Москва, ул.Ильинка 5/2, Союзпатент = (54) СПОСОБ И УСТРОЙСТВО ДЛЯ ПОЛУЧЕНИЯ МОНОКАРБОНОВЫХ КИСЛОТ ИЗ УГЛЕВОДОВ, х' ПРОИЗВОДНЫХ УГЛЕВОДОВ ИЛИ ПЕРВИЧНЫХ СПИРТОВ (57) Реферат: пропускания газа (10), стадию окисления (30) — Описываемый способ получения и стадию электроанализа. Технический монокарбоновых КИСЛОТ окислением результат состоит в окислении углеводов, их О’ соответствующих углеводов, производных производных и ...

Anti-hypercholesterolemic compounds

本发明提供式(I)的胆固醇吸收抑制剂及其可药用的盐和酯。该化合物可用于降低血浆胆固醇水平，特别是LDL胆固醇，以及治疗和预防动脉粥样硬化和动脉粥样硬化病事件。

Aldose production by degradation of sugar acid

La présente invention a pour objet un procédé de fabrication d'un aldose ou d'un dérivé d'aldose comportant sur la chaîne hydrocarbonée n atomes de carbone, caractérisé par le fait que l'on met en contact une solution aqueuse d'un dérivé acide d'ose à n+1 atomes de carbone, comportant au moins un motif alpha-hydroxyacide, ou un de ses sels, avec du peroxyde d'hydrogène en présence d'un sel de cuivre, que l'on sépare ensuite le cuivre qui précipite du milieu, puis que l'on régénère un sel de cuivre à l'aide de l'acide correspondant et que l'on recycle ensuite le sel de cuivre ainsi régénéré en tête du procédé.

COPPER DECARBOXYLATION

NEW 2,4,6-TRIIODOANILIDES 3,5-DISUBSTITUDE OF POLYHYDROXYLIC MONOACIDS

METHODS OF OBTAINING OLIGO MANNURONATES AND GULURONATES, THE PRODUCTS OBTAINED AND THEIR USES

L'invention concerne notamment un procédé d'obtention d'oligo-mannuronates saturés et/ ou insaturés, caractérisé par le fait qu'il consiste à mettre en oeuvre les étapes suivantes :a) disperser en milieu acide et à chaud des algues brunes, à un pH inférieur ou égal à 2;b) séparer, notamment par filtration, la fraction insoluble de la fraction soluble issues de l'étape a), cette fraction insoluble contenant notamment la cellulose algale des algues, et les blocs α -L-guluronique (G) et β -D-mannuronique (M); c) ajuster le pH de ladite fraction insoluble à environ 2, 8 par ajout d'une base;d) séparer, notamment par filtration, la fraction insoluble de la fraction soluble issues de l'étape c), la fraction soluble contenant des blocs d'acide ( β -D-mannuronique (M);e) soumettre ladite fraction soluble récupérée à l'étape d) à une dépolymérisation par voie acide, ou par voie enzymatique ou par voie mixte acide/ enzymatique, de manière à recueillir des oligo-mannuronates saturés et/ ou insaturés.

Process for preparing glucuronic acid or glucuronolactone

Process for the production of acylated hydrazones

Patent FR2325361B1

Method for preparing N-acetylneuraminic acid by separating and purifying polysialic acid-containing material

本发明公开了一种从含有聚唾液酸的物料中分离提纯制备N‑乙酰神经氨酸的方法，以含有聚唾液酸的物料为原料，通过除菌及固形物、除蛋白、脱色、水解、除盐、结晶等步骤获得了高纯度的N‑乙酰神经氨酸产品，经测试其纯度至少为98％，可以满足其在食品、保健、医药和化妆品等领域的要求。本发明的方法简单易操作，特别适合于工业化发酵生产N‑乙酰神经氨酸。

Algin oligosaccharides and the derivatives thereof as well as the manufacture and the use of the same

The present invention provides an alginate oligosaccharide and its derivatives with the degree of polymerization ranging from 2 to 22. The alginate oligosaccharide is composed of β-D-mannuronic acid linked by 1,4 glycosidic bonds. The derivatives with the reduced terminal in position 1 of carboxyl radical can be prepared by oxidative degradation. The present invention also provides a process for preparing the alginate oligosaccharide and its derivatives, which includes the procedures that an alginate solution is reacted for 2 to 6 h in an autoclave at pH 2-6 and the temperature of 100-120° C., and pH is adjusted to 7 after the reaction is stopped, after which the resultant oligosaccharide is oxidized in the presence of an oxidant to obtain an oxidative degradation product. The alginate oligosaccharide and its derivatives of the invention can be used in the manufacture of a medicament for the prophylaxis and treatment of AD and diabetes.

Galacturonic acid manufacturing process

Geranly compounds

This invention provides compounds having excellent antitumor activity, which are represented by the following formulae in which R 1 , R 2 , R 3 , m, n and R 4 have the significations as given in the specification.

Composition containing a water-insoluble or slightly water-soluble compound with enhanced water-solubility

A composition is disclosed comprising a water-insoluble or slightly water-soluble compound and a branched cyclodextrin-carboxylic acid. The branched cyclodextrin-carboxylic acid significantly increases the water-solubility of the compound. Also disclosed is a method of enhancing water-solubility of the compound.

Process for controlled degradation in concentrated solution of liquid glucose syrups - product thus obtained and its use as an additive for mortars and concretes

ABSTRACT OF THE DISCLOSURE A process for the controlled degradation of liquid glucose syrups in concentrated solution snd in homogeneous phase wherein the reducing groups of glucose, maltose and maltodextrin are converted into the salts of the corre-sponding aldonic acids and/or into the salts of lower carboxylic acids (C1-C4) without substantially changing the polysaccharide components (degree of poly-merization > 3) of maltodextrin, or with only partial depolymerization of the polysaccharide components, by using simple oxidants such as hypohalogenites or ferricyanides, or aqueous alyaline solutions. The conversion of the reducing sugars is equal to or greater than 95% and a very high reproductibility of the desired results is obtained. The invention also concerns the product obtained by the process and its use as an additive to cement mortars and concretes The present invention concerns a process for the controlled degradation of liquid glucose syrups in concentrated solution. More particularly, the present inven-tion concerns a process for the controllod degradation of liquid glucose syrups in concentrated solution by elminating the reducing groups in the mono-, di-and oligosaccharides.

Geranyl compounds

Pharmaceutical salts of 4'-(9-acridinylamino)methanesulfon-m-anisidide

Process for making d-glucuronic acid and its salts

METABOLITES OF INDOLYLALKYLAMINE AS 5-HYDROXYTRIPTAMINE-6 LIGANDS

ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß (19) RU (11) 2006 146 923 (13) A (51) ÌÏÊ C07D 417/12 (2006.01) ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÇÀßÂÊÀ ÍÀ ÈÇÎÁÐÅÒÅÍÈÅ (21), (22) Çà âêà: 2006146923/04, 21.06.2005 (71) Çà âèòåëü(è): ÂÀÉÅÒ (US) (30) Êîíâåíöèîííûé ïðèîðèòåò: 23.06.2004 US 60/582,290 (43) Äàòà ïóáëèêàöèè çà âêè: 27.07.2008 Áþë. ¹ 21 (87) Ïóáëèêàöè PCT: WO 2006/002125 (05.01.2006) A Àäðåñ äë ïåðåïèñêè: 190068, Ñàíêò-Ïåòåðáóðã, óë. Ñàäîâà , 51, îôèñ 303, ÎÎÎ "ÏÀÒÅÍÒÈÊÀ", ïàò.ïîâ. Ì.È.Íèëîâîé (54) ÌÅÒÀÁÎËÈÒÛ ÈÍÄÎËÈËÀËÊÈËÀÌÈÍÀ  ÊÀ×ÅÑÒÂÅ ËÈÃÀÍÄΠ5ÃÈÄÐÎÊÑÈÒÐÈÏÒÀÌÈÍÀ-6 R U 1. Ñîåäèíåíèå ôîðìóëû I A 2 0 0 6 1 4 6 9 2 3 (57) Ôîðìóëà èçîáðåòåíè â êîòîðîì Q ïðåäñòàâë åò ñîáîé CO2R5 èëè CH2NR6COR7; R1 ïðåäñòàâë åò ñîáîé Í èëè C1-C6àëêèëüíóþ ãðóïïó; R2 ïðåäñòàâë åò ñîáîé àðèëüíóþ èëè ãåòåãîàðèëüíóþ ãðóïïó, êàæäà èç êîòîðûõ ìîæåò áûòü çàìåùåíà, èëè âîçìîæíî çàìåùåííóþ 8- èëè 13-÷ëåííóþ áèöèêëè÷åñêóþ èëè òðèöèêëè÷åñêóþ êîëüöåâóþ ñèñòåìó, ñîäåðæàùóþ ìîñòèêîâûé àòîì N, è êîòîðà ìîæåò ñîäåðæàòü 1, 2 èëè 3 äîïîëíèòåëüíûõ ãåòåðîàòîìà, âûáðàííûõ èç N, Î èëè S; R3 è R4 ïðåäñòàâë þò ñîáîé íåçàâèñèìî äðóã îò äðóãà Í, ãàëîãåí, CN, OCO2R8, CO2R9, CONR10R11, CNR12NR13R14, SOmR15, NR16R17, OR18, COR19 èëè C1-C6àëêèëüíóþ, Ñ2-Ñ6àëêåíèëüíóþ, Ñ2-Ñ6àëêèíèëüíóþ, Ñ2-Ñ6öèêëîàëêèëüíóþ, öèêëîãåòåðîàëêèëüíóþ, àðèëüíóþ èëè ãåòåðîàëêèëüíóþ ãðóïïû, êàæäà èç êîòîðûõ ìîæåò Ñòðàíèöà: 1 RU 2 0 0 6 1 4 6 9 2 3 (86) Çà âêà PCT: US 2005/021852 (21.06.2005) R U (85) Äàòà ïåðåâîäà çà âêè PCT íà íàöèîíàëüíóþ ôàçó: 23.01.2007 (72) Àâòîð(û): ÂÀÍà Éîó÷ó (CA), ØÎ ×èà-×åíã (CA), ÁÅÐÍÎÒÀÑ Ðîíàëä ×àðëç (US), ÂÀÍà ×àíã-×èè Ïîë (US), ÊÀÈ Ïèíã (US), ÂÀÍà Æè (US) áûòü çàìåùåííîé; R5 è R5 ïðåäñòàâë þò ñîáîé íåçàâèñèìî äðóã îò äðóãà Í èëè C1-C5àëêèëüíóþ ãðóïïó; R7 ïðåäñòàâë åò ñîáîé C1-C6àëêèëüíóþ ãðóïïó ; èëè m ðàâíî 0 èëè öåëîå ÷èñëî 1 èëè 2; A 2 0 0 6 1 4 6 9 2 3 R U A Ñòðàíèöà: 2 2 0 0 6 1 4 6 9 2 3 5. Ñîåäèíåíèå ïî ï.1, âûáðàííîå èç ãðóïïû, âêëþ÷àþùåé: N-(2-{1-[(6-õëîðèìèäàçî[2,1-b][1 ...

Improvements in or relating to organic silver compounds and the production thereof

An antiseptic agent based upon a silver-polyuronate compound is obtained by partially depolymerizing alginic acid by heating, and reacting the product with a solution of a silver salt, e.g. silver carbonate. Another oligodynamic metal (e.g. gold) may be substituted for silver.ALSO:A soap includes an antiseptic agent which is obtained by partially depolymerizing alginic acid by heating, and reacting the product with a silver salt, e.g. silver carbonate, to which reaction product is added potassium permanganate. The soap may be prepared from castor oil, olive oil and oleic acid.ALSO:An antiseptic based upon a silver-polyuronate compound is obtained by partially depolymerizing alginic acid by heating, and reacting the product with a solution of a silver salt, e.g. silver carbonate. Enhanced germicidal properties may be accomplished by combining the reaction product with an oxidising agent, e.g. potassium permanganate, and by the substitution of the silver by another oligodynamic metal (e.g. gold). Soap may be present.

Derivatised carbohydrates and their use in solid delivery systems

In a composition comprising a therapeutic agent and a compound which is a trisaccharide or higher polysaccharide, that compound has the formula X[-Y-Z] n wherein X and Z are each saccharide molecules in which none, some or all OH groups are derivatised; Y is an ester linkage to an exocyclic C atom in X; and n in an integer.

Escherichia coli and application thereof in production of polysialic acid

本发明公开了一株大肠埃希氏菌及其在产聚唾液酸中的应用。本发明自行筛选了一株聚唾液酸生产效率和产量均较高的大肠埃希氏菌，采用该菌株生产聚唾液酸时，不仅能缩短生产时间，降低生产成本，还能得到较高产量的聚唾液酸，具有很好的工业应用前景。

ALKYLGALACTOSIDES ALKYL URONATES, THEIR PREPARATION PROCESS AND THEIR APPLICATIONS, IN PARTICULAR AS NON-IONIC SURFACTANTS.

Les alkylgalactosides uronates d'alkyle de formule: (CF DESSIN DANS BOPI) R1 étant alkyle linéaire ou ramifié ayant de 2 à 22 atomes de carbone, sont des agents tensio-actifs. The alkylgalactosides uronates of alkyl of formula: (CF DRAWING IN BOPI) R1 being linear or branched alkyl having from 2 to 22 carbon atoms, are surfactants.

The preparation of saccharide carboxylic acids

一种糖羧酸及其盐的产生方法，其特征在于属于 假葡萄糖杆菌属的能氧化羟甲基和/或半缩醛羟基 碳原子为羧基的微生物或由此微生物制得的细胞制 品作用于含羟甲基和/或半缩醛羟基的糖或糖衍生 物以产生及积累相应的羧酸以及获取这些羧酸，和通 过以上方法得到的新的糖羧酸。通过本方法，高选择 性高产率地从许多糖产生带有羧基(由羟甲基和/或 半缩醛羟基氧化而来)的糖酸，生成的糖酸具有抗酶 降解及增加水溶性及其它特点。

Process for the alcaline oxidative degradation of reducer sugars and products thus obtained

The invention relates to a process for the alcaline oxidative degradation of an ose, an ulose, polymers or mixtures thereof in aqueous solution and in the presence of a redox couple comprised of a mixture of monosulfonic anthraquinone-2-acid and of hydrogen peroxide, characterized in that the oxidant gas is air and said air is stirred up and introduced into the reaction medium in agitation flow rate conditions and such that the dissolved oxygen saturation of the reaction medium gives a pink coloration of said reaction medium.

Low molecular weight hyaluronic acid for the treatment of nerve damage

The present invention provides a therapeutic agent for nerve damages such as those caused by spinal cord injury or nerve trauma, which comprises, as an active ingredient, a low-molecular-weight saccharide composed of at least glucuronic acid and/or N-acetylglucosamine or a pharmaceutically acceptable salt thereof. The present invention also provides a therapeutic agent for nerve damages which comprises, as an active ingredient, preferably a low-molecular-weight hyaluronic acid, more preferably hyaluronic acid disaccharide to hyaluronic acid 2,500-saccharide, further more preferably hyaluronic acid disaccharide to hyaluronic acid 50-saccharide, much more preferably hyaluronic acid tetrasaccharide, or a pharmaceutically acceptable salt thereof.

Controlled decomposition of liquid glucose syrup and cement adduct obtained thereby

Method of preparing metal ion complex with oligo-or polygalacturonic acids

Novel complexes of oligo- and polygalacturonic acids formed with essential metal ions and having the general formula (I), <IMAGE> (I) wherein n is an integer from about 10 to about 145 M represents at least two metal cations selected from the group consisting of iron(II), copper(I), copper(II), magnesium(II), potassium(I), cobalt(II), manganese(II), zinc(II), chromium(III), molybdenum(V), vanadium(IV) and nickel(II) with the proviso that one of the ions must represent potassium(I) or magnesium(II), and z is an integer corresponding to the charge or the valence number of the metal atom are useful in foodstuffs and pharmaceutical preparations for administering essential elements to humans.

Polyuronic acid choline-metal salts

3,5-disubstituted-2,4,6-triiodoanilides of polyhydroxy-monobasic acids

1514685 X-Ray contrast agent MALLINCKRODT INC 28 Sept 1976 [29 Sept 1975] 40193/76 Heading A5B [Also in Division C2] An X-ray contrast agent comprises 3 - gluconanulo - 5 - [N - (2 - hydroxyethyl)] acetamido - 2, 4, 6 - triiodo - N - methyl - benzamide; 3 - (2 - keto - L - gulonamido) - 5 - [N - (2 - hydroxyethyl)] acetamido - 2, 4, 6 - triiodo - N - methyl - benzamide; or 3, 5 - bis (D - gluconamido) - 2, 4, 6 - triiodo - N - methyl - benzamide.

Indolyalkylamine metabolites such as 5-hydroxytrythamine-6 ligands

Foreliggende oppfinnelse tilveiebringer en forbindelse med formel I og anvendelsen derav for terapeutisk behandling av lidelser relatert til eller påvirket av 5-HT6-reseptoren.

Synthetic heparin pentasaccharides

Preparation of synthetic monosaccharides, disaccharides, trisaccharides, tetrasaccharides and pentasaccharides for use in the preparation of synthetic heparinoids.

Method of producing salts of 4'-(9-acridinylamino)-methansulfon-m-anisidine

For use as, inter alia, an anti-neoplastic agent, there is disclosed a compound of the formula:- <CHEM> wherein X is an acid having a total of from three to six carbon atoms, two to five hydroxy groups and an acidic group selected from -CO2H and -OPO3H2 with the proviso that, when the total number of carbon atoms is three or four, the acidic group is -OPO3H2. These particular salts of 4 min -(9-acridinylamino)methanesulfon-m-anisidide remain in solution for a reasonable period and hence permit the use of the compound in this salt form for introduction into a mammal. Also disclosed are the processes for producing the salts and pharmaceutical compositions including the salts.

Deacetylcolchicine derivatives

Glycolipids for serodiagnosis of tuberculosis and leprosy

ABSTRACT OF THE DISCLOSURE A method of testing for tuberculosis and leprosy in animals, or humans and antigens used in the method. The method involves carrying out an assay on sera from said humans or animals using an antigen to bind antibodies in said sera. The antigens used in the method are synthetic pseudo cord factor-like glycolipids having the structures (I) or (II) below:

The manufacturing method of the acid monomers of seaweed containing metallic crystal

本发明公开了一种含金属晶体海藻酸单体结构的制造方法，包括以下步骤：(S1)提供海藻酸高分子溶液，包括具有数个海藻酸单体；(S2)加入自动还原剂与金属前驱物于海藻酸高分子溶液中，形成混合溶液，自动还原剂占混合溶液0.05％～0.2％(w/v)，且金属前驱物占混合溶液的0.1～6mM；以及(S3)微波加热混合溶液5～30分钟。本发明方法制作出的含金属海藻酸单体结构具有良好的稳定性以及金属晶体均匀性，且其金属晶体具有20nm～712nm之间的粒径，并且可以藉由调整成份比例、微波功率以及微波时间，有效控制金属晶体尺寸，使金属晶体尺寸落在适用于人体且具有良好抗菌效果的范围内，达到良好的抗菌效果。

SYNTHESIS PROCESS AND NOVEL DERIVATIVES OF A, L-IDURONIC ACID

Method for producing sugar carboxylic acid

슈도글루코노박터 속에 속하며 히드록시메틸기 및/또는 헤미아세탈 히드록실-결합 탄소원자를 카르복실기로 산화시킬 수 있는 미생물 또는 이 미생물로부터 유래된 제제를 히드록시메틸 및/또는 헤미아세탈 히드록실-함유 당 또는 당유도체에 작용시켜 상응하는 카르복실산을 생산 및 축적시키고 이렇게 축적된 카르복실산을 분리함을 특징으로 하는 당 카르복실산 또는 그의 염의 제조방법 및 상기한 제조 방법에 의해 제조된 신규의 당 카르복실산, 및 이 제조방법에 의해서 넓은 범위의 당으로부터, 히드록시메틸 및/또는 헤미아세탈 OH기로부터 유래된 카르복실기를 갖는 당산을 고 선택성 및 고수율로 제조할 수 있으며, 생성된 당산은 특히 효소적 분해에 대해 내성이 있으며 수용성이 향상된다.

Process for the preparation of uronic acid derivatives

Process for selective oxidation of primary alcohols

Novel disaccharides with anti-arthritic action

This invention refers to new disaccharides of formula (I), (see formula I) where R1 is selected from the group consisting of hydrogen, linear or bran-ched (C1-C4)-alkyl, phenylalkyl of less than ten carbon atoms and -COCH3; R2 is selected from the group consisting of hydrogen, -COCH3 and SO3M; R3 is selected from the group consisting of hydrogen, linear or branched (C1--C4)-alkyl, phenylalkyl of less than ten carbon atoms, -COCH3 and -COPh, where Ph is phenyl; G is selected from between -COOR4 and -COOM, whe-re R4 is selected from the group consisting of hydrogen, (C1-C2)-alkyl and arylalkyl of less than sixteen carbon atoms; A is selected from the group consisting of hydrogen, -SO3H, -SO3M and -COCH3; B is selected from the group consisting of hydrogen, -SO3H, -SO3M and -COCH3; where either A or B are necessarily either -SO3H or -SO3M, and where M is an organic or me-tallic cation. These compounds can be used as anti-arthrosic or anti--inflammatory drugs or to control blood clotting.

Disaccharides for the treatment of tendons and ligaments

Uso de un compuesto de fórmula (I),**Fórmula** en la que: R1 es hidrógeno, C1-C4 alquilo lineal o ramificado, fenilalquilo de menos de diez átomos de carbono o - COCH3; R2 es hidrógeno, -COCH3 o -SO3Y; R3 es hidrógeno, C1-C4 alquilo lineal o ramificado, fenilalquilo de menos de diez átomos de carbono, -COCH3 o -COPh, donde Ph es fenilo; G es -COOR4 o -COOY, donde R4 es hidrógeno, C1-C2 alquilo o arilalquilo de menos de dieciséis átomos de carbono; A es hidrógeno, -SO3H, -SO3Y o -COCH3; y B es hidrógeno, -SO3H, -SO3Y, o -COCH3, en donde necesariamente o A o B es o bien -SO3H, o bien -SO3Y, donde Y es un catión orgánico o inorgánico; así como sus solvatos y sus sales farmacéuticas aceptables, para la preparación de un medicamento para el tratamiento o prevención de una enfermedad, trastorno o lesión de tendón o ligamento en un mamífero. Use of a compound of formula (I), ** Formula ** in which: R1 is hydrogen, C1-C4 linear or branched alkyl, phenylalkyl of less than ten carbon atoms or - COCH3; R2 is hydrogen, -COCH3 or -SO3Y; R3 is hydrogen, C1-C4 linear or branched alkyl, phenylalkyl of less than ten carbon atoms, -COCH3 or -COPh, where Ph is phenyl; G is -COOR4 or -COOY, where R4 is hydrogen, C1-C2 alkyl or arylalkyl of less than sixteen carbon atoms; A is hydrogen, -SO3H, -SO3Y or -COCH3; and B is hydrogen, -SO3H, -SO3Y, or -COCH3, where necessarily either A or B is either -SO3H, or -SO3Y, where Y is an organic or inorganic cation; as well as its solvates and its acceptable pharmaceutical salts, for the preparation of a medicament for the treatment or prevention of a disease, disorder or injury of tendon or ligament in a mammal.

Galacturonic acid derivs for hepatic compla- - ints treatment

New derivs. of galacturonic acid are used for treatment of hepatic disorders. Specif. derivs is choline galacturonate (I). Medicament is pref. administered in the form of tablets or drinkable ampoules in amounts of 1-5g of active ingredient per day. Cpd. (I) is specif. used as a veterinary hepato-protecting agent. In humans, cpds. (I) had detociant and lipotropic activity.

Hyaluronic acid oligosaccharide fraction and pharmaceuticals containing it

４糖〜６０糖から選択されるサイズを有するヒアルロン酸オリゴ糖、該ヒアルロン酸オリゴ糖を含有し、特定の理化学的性質を有することを特徴とする画分、及びそれらを含む医薬。本発明のヒアルロン酸オリゴ糖は、細胞死抑制剤、細胞障害抑制剤、及び細胞・組織保護剤（例えば、臓器保存剤、潰瘍処置剤、肝障害処置剤、ＩＬ−１０産生促進剤、またはＩＬ−８産生抑制剤）の有効成分として優れた薬理効果を発揮し、かつその安全性も高いことから極めて有用である。

Alkali metal salts and alkaline earth metal salts of n-isonicotinylhydrazine n-glucuronide and a process for their production

The invention comprises alkali and alkaline-earth metal salts of N-isonicotinylhydrazine N1-glucoronide having the formula <FORM:0876607/IV (b)/1> wherein M represents an alkali metal or one equivalent of an alkaline-earth metal, and the preparation thereof by reacting an alkali or alkaline-earth metal salt of glucuronic acid with isonicotinic acid hydrazide. Preferably the process is carried out at 70-80 DEG C. and a lower aliphatic alcohol is added, such that the alcohol concentration of the solution is 50-80%, to induce crystallisation. Examples describe the preparation of the sodium and calcium salts of N-isonicotinylhydrazide N1-glucuronide, either methanol or ethanol being added to induce crystallisation of the salts.

Glycuronamides, glycosides and orthoester glycosides of fluoxetine, analogs and uses thereof

Process for the production of uronic acids, in particular glucuronic acid

Novel disaccharides with anti-arthrosic properties

The invention relates to novel disaccharides of formula (I), wherein R 1 is selected from the group consisting of hydrogen, linear or branched (C 1 -C 4 ) alkyl, phenylalkyl with less than ten carbon atoms and —COCH 3 ; R 2 is selected from the group consisting of hydrogen, —COCH 3 and SO 3 M; R 3 is selected from the group consisting of hydrogen, linear or branched (C 1 -C 4 ) alkyl, phenylalkyl with less than ten carbon atoms, —COCH 3 and y —COPh, Ph being phenyl; G is selected from amongst —COOR 4 and —COOM, R 4 is selected from the group consisting of hydrogen, (C 1 -C 2 )-alkyl and arylalkyl with less than sixteen carbon atom; A is selected from the group consisting of hydrogen, —SO 3 H, —SO 3 M and —COCH 3 ; B is selected from the group consisting of hydrogen, —SO 3 H, —SO 3 M and —COCH 3 , wherein either A or B are necessarily either —SO 3 H or —SO 3 M, M being a an organic or metallic cation. Said compounds can be used as anti-arthritic agents, anti-inflammatory agents or to control blood coagulation.

Process for selective oxidation of primary alcohols

A process for oxidising a primary alcohol using an oxidising agent in the presence of a catalytic amount of a di- tertiary-alkyl nitroxyl, characterized in that the oxidising agent is a peracid or a precursor thereof, and the oxidation is carried out in the presence of 0.1-40 mol% of halide, with respect to the primary alcohol.

Detection of oligosaccharides

Provided herein are processes for detecting oligosaccharides in a biological sample. In specific instances, the biological sample is provided from an individual suffering from a disorder associated with abnormal glycosaminoglycan accumulation.

Selective oxidation process of oligosaccharide primary alcohol

Cyclopentenones, process for preparing the same, and the use thereof

A process for preparing 4,5-dihydroxy-2-cyclopenten-1-one represented by formula (1), characterized by heat-treating at least one member selected among: (a) uronic acids or uronic acid derivatives; (b) sugar compounds containing uronic acids and/or uronic acid derivatives; and (c) sugar compound-containing materials containing uronic acids and/or uronic acid derivatives.

Process for selective oxidation of primary alcohols

Primary alcohols, especially in carbohydrates, can be selectively oxidised to aldehydes and carboxylic acids in a low-halogen process by using a peracid in the presence of a catalytic amount of a di-tertiary-alkyl nitroxyl (TEMPO) and a catalytic amount of halide. The halide is preferably bromide and the process can be carried out at nearly neutral to moderately alkaline pH (5-11). The peracid can be produced or regenerated by means of hydrogen peroxide or oxygen. The process is advantageous for producing uronic acids and for introducing aldehyde groups which are suitable for crosslinking and derivatisation.

Imaging agent and application method

一种显像剂及其用于对受试者组织中的坏死进行成像的方法。成像方法可以是正电子发射断层扫描(PET)。在至少一个实施方案中，显像剂包含2‑脱氧‑2‑[ 18 F]氟代葡萄糖二酸(18F‑FGA)或其药学上可接受的盐。显像剂可以置于药学上可接受的赋形剂、载体、稀释剂或媒介物中。显像剂可以包含在试剂盒中。在至少一个实施方案中，本公开包括制备用于成像的放射性药物如 18 F‑FGA的方法。

Process for the manufacture of d-glucuronic acid

d-Glucuronic acid is obtained by subjecting vegetable gums, particularly acacia gum, to hydrolysis in an acid reacting medium. In an example, gum arabic is dissolved in 5 per cent sulphuric acid and maintained at 100 DEG C. for about 10 hours, the completion of hydrolysis being determined by the absence of further change in the optical activity of the solution containing the operation. The sulphuric acid is neutralized, first with baryta water and then with barium carbonate and the solution decolourized with carbon if necessary, is filtered and concentrated. The barium salt of glucuronic acid is then precipitated by adding alcohol, the admixed sugars remaining in solution.

Process for selective oxidation of primary alcohols of oligosaccharides

본 발명은 촉매량의 디-tert-알킬 니트록실 자유 라디칼을 사용하여 올리고사카라이드의 일차 알콜을 선택적으로 산화시켜 그 알콜에 상응하는 카르복실산 유도체를 형성시키는 방법에 있어서, 산화제로서 1,3-디브로모-5,5-디메틸히단토인 또는 1,3-디클로로-5,5-디메틸히단토인을 사용하고, 반응을 pH ＜10의 중성 내지 염기성 조건 하에 수행하는 것이 특징인 방법에 관한 것이다. The present invention provides a method of selectively oxidizing a primary alcohol of an oligosaccharide using a catalytic amount of di-tert-alkyl nitroxyl free radicals to form a carboxylic acid derivative corresponding to the alcohol, wherein 1,3- is used as an oxidizing agent. A method is characterized by using dibromo-5,5-dimethylhydantoin or 1,3-dichloro-5,5-dimethylhydantoin and carrying out the reaction under neutral to basic conditions of pH <10. 상기 본 발명의 방법은 카르복실레이트기를 함유하는 (부분적으로 보호되어 있는) 올리고사카라이드, 이들의 중간체 및 최종 생성물을 제조하는 데 유용하다. The process of the present invention is useful for preparing (partially protected) oligosaccharides containing carboxylate groups, intermediates thereof and final products.

Process for preparing pharmaceutically acceptable 4'-/9-acridinyl-amino/-methansulphone-m-anizidide salts

Urea and uronic acid adducts prepn. useful in cosmetics

Prepn. of urea-uronic acid adducts (I) comprises reacting urea with a uronic acid and/or uronic acid lactone in aq. soln. without a catalyst.

Sucrosetricarboxylic acid and compositions containing the same

Sucrosetricarboxylic acid can be prepared by oxidizing sucrose with oxygen, if desired in a mixture with inert gases, by means of a more effective catalyst than platinum/alumina. The product can be used in washing agents or as a food additive.

Hyaluronic acid oligosaccharide fractions and drugs containing the same

本发明提供具有选自4糖～60糖大小的透明质酸低聚糖；含有该透明质酸低聚糖、且具有特定理化性质的级分；和含有这些物质的药品。本发明的透明质酸低聚糖，作为细胞死亡抑制剂、细胞障碍抑制剂，及细胞、组织保护剂(例如器官保存剂、溃疡处置剂、肝脏障碍处置剂、IL-10产生促进剂，或IL-8产生抑制剂)的有效成分，发挥优良的药理效果，且具有很高的安全性，因而极其有用。

Process for producing 1-fluoro-glycuronic acids and their salts and such new 1-fluoro-glyconic acids and their salts

Abstract of the disclosure: Process for the preparation of 1-fluoro-glycuronic acids and salts thereof, and such novel 1-fluoro-glycuronic acids and salts thereof Process for the preparation of 1-fluoro-glycuronic acids, which can contain protected amino groups, and salts thereof, characterized in that glycopyranosyl fluorides of mono- or oligosaccharides which carry at least one primary OH function are oxidized with oxygen as the oxidizing agent in an aqueous solution in the pH range from 6 to 9 in the presence of a catalyst which contains at least one platinum metal, and the 1-fluoro-glycuronic acids formed are at least partly neutralized. The invention furthermore relates to compounds of the general formula (I)

PRIMARY ALCOHOL OXIDATION PROCEDURE

En un nuevo procedimiento para la oxidación de un alcohol primario y/o secundario, se emplea un agente oxidante en presencia de un di-terc-alquilnitroxilo, en un medio de reacción acuoso a un pH por debajo de 7. El di-terc-alquilnitroxilo es en especiaI4-hidroxi-TEMPO y el proceso se lleva a cabo en particular para la oxidación de carbohidratos tal como almidón. In a new process for the oxidation of a primary and / or secondary alcohol, an oxidizing agent is used in the presence of a di-tert-alkylnitroxy, in an aqueous reaction medium at a pH below 7. The di-tert- Alkyl nitroxy is in particular I-4-hydroxy-TEMPO and the process is carried out in particular for the oxidation of carbohydrates such as starch.

Enteromorpha polysaccharide, enteromorpha oligosaccharide, pharmaceutical composition and application thereof

本发明公开了浒苔多糖及其降解产物浒苔寡糖在抗菌方面的用途。本发明的浒苔多糖及其降解产物浒苔寡糖,或其与抗生素物理混合物对已经形成的细菌生物膜具有较强的破坏作用，杀菌范围广，对生物膜的形成具有良好的抑制作用。同时，所述浒苔多糖及其降解产物浒苔寡糖,或其与抗生素物理混合物能够有效降低细菌以生物膜形式存在时产生的耐药性，提高细菌对传统抗生素的敏感性，降低传统抗生素的使用量。

Pharmaceutically acceptable salts of 4'-(9-acridinylamino)methanesulfon-m-anisidide,their production,and pharmaceutical compositions containing such salts

For use as, inter alia, an anti-neoplastic agent, there is disclosed a compound of the formula:- wherein X is an acid having a total of from three to six carbon atoms, two to five hydroxy groups and an acidic group selected from -CO2H and -OPO3H2 with the proviso that, when the total number of carbon atoms is three or four, the acidic group is -OPO3H2. These particular salts of 4 min -(9-acridinylamino)methanesulfon-m-anisidide remain in solution for a reasonable period and hence permit the use of the compound in this salt form for introduction into a mammal. Also disclosed are the processes for producing the salts and pharmaceutical compositions including the salts.

Method of obtaining an organic salt or acid from an aqueous sugar stream

A process for obtaining one or more than one salt of an organic acid(s), or organic acid(s), from an aqueous sugar stream comprising one or more than one mineral acid and the organic acid(s) is provided. The process comprises introducing the aqueous sugar stream to a separation system comprising one or more beds of anion exchange resin and obtaining a stream therefrom compri sing the sugar. The one or more beds of anion exchange resin are then regene rated in one or more stages to produce at least one product stream comprisin g the organic acid, a salt of the organic acid, or a combination thereof, an d a separate outlet stream comprising the mineral acid, a salt of the minera l acid, or a combination thereof. The product stream is then recovered. The separation may be conducted with two separation units, or using a single ani on exchange unit.

Imaging agents and methods of use

An imaging agent and a method of its use for imaging a necrosis in a tissue of a subject. The imaging method may be positron emission tomography (PET). In at least one embodiment the imaging agent comprises 2-deoxy-2-[18F]fluoroglucaric acid (18F-FGA), or a pharmaceutically-acceptable salt thereof. The imaging agent may be disposed in a pharmaceutically-acceptable excipient, carrier, diluent, or vehicle. The imaging agent may be contained within a kit. The disclosure includes in at least one embodiment a method of preparing a radiopharmaceutical such as 18F-FGA for use in imaging.